Table 2.

GEC Cytotoxicity

A	BCECF-specific release (%)
	5% vol/vol	2.5% vol/vol	1.25% vol/vol
Normal serum	77 ± 4*	52 ± 4*	20 ± 3*
C8DS+C8	55 ± 7	17 ± 7	9 ± 5

B	LDH-specific release (%)
	10% vol/vol	5% vol/vol	2.5% vol/vol
Normal serum	61 ± 9	17 ± 8	0 ± 0
Normal serum+ AG1478	67 ± 11	19 ± 7	0 ± 0

A: GEC were incubated with BCECF-acetoxymethyl ester and then incubated with either antibody and complement (normal serum or C8DS+C8) or heat-inactivated serum in controls. Supernatants were collected and cells were permeabilized with digitonin to release remaining BCECF. BCECF content was measured by spectrofluorometry. Specific release is calculated as (E − C)/(100 − C), where E is the percent released in complement-treated cells and C is the percent released in control incubations (heat-inactivated serum). Significantly greater BCECF release was present in normal serum groups, as compared with C8DS+C8 groups (*P < 0.0001 ANOVA; 3 experiments).

B: GEC were incubated with or without AG1478, 300 nmol/L and with antibody and normal serum, or with heat-inactivated serum in controls. Supernatants were collected and cells were permeabilized with digitonin to release remaining lactate dehydrogenase (LDH). LDH activity was assayed in supernatants and digitonin-treated cells, and specific release was calculated as above. There are no significant differences between AG1478-treated and untreated groups (4 experiments).